Compare Ecopetrol SA (EC) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Eli Lilly And Co — how do they compare? Ecopetrol SA trades at $15.94 (market cap $30.44B), while Eli Lilly And Co trades at $1,171.68 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 33.8× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (4.06%). Which is the better fit depends on your goals.
| EC | LLY | |
|---|---|---|
Market Cap | $30.44B | $1.03T |
Sector | Energy | Health |
52-Week High | $16.58 | $1.24K |
52-Week Low | $8.29 | $625.65 |
Enterprise Value | $58.23B | $1.07T |
Dividend Yield | 4.06% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $15.93, down 1.42% with mixed technical signals showing bullish moving averages but bearish oscillators. The company maintains solid profitability with 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6B in 2022 to $119.7B in 2025. Recent developments include a collective bargaining agreement with workers and upcoming Q2 2026 earnings release on August 3, 2026.
While valuation appears reasonable with P/E of 11.39, declining revenue trends and recent earnings misses pose challenges. Analyst consensus is cautious with 54.55% hold rating and $14.63 price target below current levels. Key risks include oil price volatility and execution challenges in a competitive energy sector.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
